LONDON, ONTARIO / ACCESS Newswire / February 26, 2026 / For pet owners, confidence matters. Knowing where to turn for the right products, reliable guidance and genuine care can make all the difference. Southwest Pet has been recognized with the 2026 Consumer Choice Award in the Pet & Aquarium Centre category, highlighting its role as a trusted, customer focused retailer serving pet owners across the London community.
Southwest Pet specializes in high quality products for dogs and cats, offering a carefully selected range that supports everyday care, nutrition and enrichment. Beyond traditional pet retail, the store is also known for its expertise in reptiles and exotic animals, providing knowledgeable guidance that helps customers navigate the unique needs of less common pets.
What sets Southwest Pet apart is its commitment to education and service. The team takes time to understand each customer’s situation, whether they are welcoming a new pet, managing specific care requirements or exploring exotic species for the first time. This personalized approach creates a shopping experience that feels supportive rather than transactional, empowering customers to make informed decisions.
The store’s welcoming environment and friendly service encourage conversation, questions and learning. Customers value the ability to access trusted advice alongside quality products, knowing they are supported by a team that prioritizes animal well-being and responsible pet ownership.
Receiving the 2026 Consumer Choice Award reflects the strong relationships Southwest Pet has built with its customers. “We are proud to be recognized by the London community,” said the team at Southwest Pet. “Our goal has always been to help people care for their pets with confidence by offering reliable products, honest guidance and a positive in store experience.”
Consumer Choice Award highlights businesses that earn consistent support within their communities by delivering value and service. For Southwest Pet, this recognition underscores its dedication to creating an engaging retail experience rooted in knowledge, care and trust.
As Southwest Pet looks ahead, the team remains committed to supporting pet owners at every stage of their journey. By combining quality products with expert advice and friendly service, the store continues to be a go to destination for pet care in London.
About Southwest Pet Southwest Pet is a customer focused pet retailer based in London, Ontario. Specializing in dog and cat products while offering expert guidance on reptiles and exotic animals, the store provides high quality products, trusted advice and friendly service. Southwest Pet is dedicated to helping customers confidently care for their pets through knowledge, support and an engaging in store experience. To learn more, visit www.southwestpet.ca.
About Consumer Choice Award Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.
Contact Information Sumi Saleh Communications Manager ssaleh@ccaward.com
LONDON, ONTARIO / ACCESS Newswire / February 26, 2026 / Larlyn Property Management Ltd. has received the 2026 Consumer Choice Award in the Property Management category, marking a notable recognition for a Canadian firm with more than 50 years of experience in the industry.
Larlyn provides full-service property management for condominiums, residential rental properties, and commercial assets. The firm also works closely with developers and investors on new construction projects and property conversions, supporting properties from early development through long-term operation.
Operating with a combination of local market expertise and national resources, Larlyn delivers financial, technical, and operational management services designed to meet the evolving needs of property owners and stakeholders. This structure allows the firm to manage diverse portfolios while maintaining consistency, regulatory compliance, and operational oversight.
Larlyn’s work is supported by recognized industry certifications, including ACMO 2000 and IREM AMO. These designations reflect established standards in governance, financial controls, and professional management practices within the property management sector.
Over the years, the firm has developed long-standing relationships with condominium boards, property owners, developers, and institutional partners. Its approach emphasizes planning, accountability, and long-term asset performance in environments where expectations and regulatory requirements continue to evolve.
“This recognition reflects the work our teams do every day to manage properties responsibly and consistently,” said the team at Larlyn Property Management Ltd. “With more than 50 years of experience, our focus remains on long-term performance, professional standards, and supporting the clients and communities we serve.”
Recognition through the 2026 Consumer Choice Award reflects Larlyn’s continued presence in the London market and its ongoing role in managing residential and commercial properties with a structured, professional approach.
As Larlyn continues its work in London and across Canada, the firm remains focused on delivering property management services grounded in experience, operational discipline, and industry standards.
About Larlyn Property Management Ltd. Larlyn Property Management Ltd. is a Canadian property management firm with over 50 years of experience. The company provides full-service management for condominiums, residential rentals, and commercial properties, and partners with developers and investors on new construction and conversion projects. Supported by certifications including ACMO 2000 and IREM AMO, Larlyn combines local market expertise with national resources to deliver financial, technical, and operational property management services. To learn more, visit www.larlyn.com.
About Consumer Choice Award Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.
Contact Information Sumi Saleh Communications Manager ssaleh@ccaward.com
LONDON, ONTARIO / ACCESS Newswire / February 26, 2026 / Bath Fitter has been recognized with the 2026 Consumer Choice Award in the Bathroom Remodelling category, recognizing the company’s continued delivery of high quality bathroom renovation solutions for residential and commercial clients in the London region.
Founded in 1984, Bath Fitter introduced a concept that changed the renovation industry. Instead of removing existing tubs and showers, the company developed a method to install custom made acrylic bath and shower systems directly over existing fixtures. This approach delivers a clean, modern result without the mess, extended timelines or stress commonly associated with traditional remodelling projects.
What sets Bath Fitter apart is its fully customized process. Every bathtub and shower is manufactured to order in the company’s own facilities, ensuring precise measurements, consistent quality and a seamless finish. Certified installation technicians complete most projects in as little as one day, allowing customers to enjoy an upgraded bathroom almost immediately with minimal interruption to their routine.
Design flexibility plays a central role in the Bath Fitter experience. Customers can choose from a wide range of modern styles, colours, wall patterns, shelving options, doors and accessories. Safety features such as slip resistant surfaces and grab bars are also available, making it easier to create bathrooms that are not only stylish but accessible and comfortable for long term use.
Durability is built into every installation. Bath Fitter’s acrylic products are engineered to resist stains, scratches and mildew while remaining easy to clean and maintain. The seamless, one-piece wall system eliminates grout lines, creating a contemporary appearance that reduces ongoing upkeep. Many installations are supported by a lifetime warranty, reinforcing the company’s focus on lasting value and customer confidence.
While Bath Fitter is widely known for residential projects, the company also supports a broad range of commercial clients. Hotels, healthcare facilities, senior living communities, student housing providers and property management firms rely on Bath Fitter’s rapid installation process to modernize bathrooms without taking rooms or units out of service for extended periods.
With hundreds of locations across Canada and the United States, Bath Fitter combines the strength of a recognized North American brand with the personalized care of local teams. In home and virtual consultations allow customers to explore design options, receive expert guidance and obtain clear, accurate quotes before committing to a project.
Receiving the 2026 Consumer Choice Award reflects Bath Fitter’s continued emphasis on craftsmanship, efficiency and innovation. By offering a renovation solution that balances speed, quality and design, Bath Fitter remains a trusted choice for those looking to modernize bathrooms with confidence.
About Bath Fitter Bath Fitter is a leading North American bathroom remodelling company founded in 1984. Known for its seamless, custom-made acrylic bath and shower systems, the company provides fast, durable renovation solutions without demolition. Serving residential and commercial clients, Bath Fitter combines personalized design, professional installation and long-term value through innovative processes and quality craftsmanship. To learn more, visit www.bathfitter.com.
About Consumer Choice Award Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.
Contact Information Sumi Saleh Communications Manager ssaleh@ccaward.com
A Nut-Free, 110-Calorie Bar Designed for Today’s On-the-Go Consumers
CHARLOTTE, NORTH CAROLINA / ACCESS Newswire / February 26, 2026 / Truly Good Foods, the women-owned, second-generation, family-operated snack manufacturer known for delivering premium, innovative snacking solutions, today announced the launch of Golden Hour™, a new line of craveable snack bars that prove better-for-you can still mean genuinely delicious.
At just 110 calories per bar and produced in a dedicated nut-free facility, Golden Hour™ was created for modern consumers who expect more from their snacks. And for the operators who need delicious and high-velocity options they can trust. The line debuts with four craveable flavors: Berry Vanilla, Banana Bread, Cherry Chocolate, and Apple Cinnamon.
Golden Hour™ bars are peanut-free, tree-nut-free, dairy-free, soy-free, and low sodium, making them an ideal solution for schools, healthcare facilities, corporate offices, hospitality, and anywhere dietary sensitivities and allergen concerns matter. In a category often dominated by compromise, Golden Hour™ delivers both simplicity and satisfaction.
“Golden Hour is about creating a snack moment people can feel good about,” said Lisa Smith, VP of Sales and Marketing. “It’s a reminder to slow down, find the joy in everyday moments, and make every hour your Golden Hour.”
The launch features four standout granola bar flavors designed to feel nostalgic, elevated, and unmistakably craveable:
Apple Cinnamon – Apple, cinnamon, roasted pumpkin seeds, white chips, and whole rolled oats
Cherry Chocolate – Cherries, semi-sweet chocolate chips, chia seeds, golden flax, quinoa, and whole rolled oats
Berry Vanilla – Blueberries, infused cranberries, chia seeds, golden flax seeds, quinoa, and whole rolled oats
The introduction of Golden Hour™ reflects Truly Good Foods’ broader strategic momentum. Over the past several years, the company has accelerated its branded growth strategy, expanded manufacturing capacities, and strengthened its position as a trusted partner across foodservice, retail, and B2B channels. Golden Hour™ represents the next phase of that evolution, leveraging category insight and a commitment to innovation to meet rising demand for better-for-you, allergen-conscious snacks.
Golden Hour™ joins Truly Good Foods’ expanding portfolio of branded products, including Henrietta Said, Grabeez, and the company’s namesake Truly Good Foods line.
CRANBROOK, BRITISH COLUMBIA / ACCESS Newswire / February 26, 2026 / Eagle Plains Resources Ltd. (TSX-V:EPL)(OTCQB:EGPLF) (“EPL” or “Eagle Plains”) is pleased to announce it has entered into a purchase and sale agreement with Trident Resources Corp. (TSX-V:ROCK)(OTCQB:TRDTF )(“Trident ” or ” the Company”) on seven individual non core claim blocks totalling 4,711 ha. Under the terms of the agreement, dated February 25, 2026, Trident will purchase a 100% interest in the properties for a cash consideration of $5,000, with EPL retaining a 2% Net Smelter royalty on all of claims, one half of which may be purchased by Trident for $1,000,000. The projects are located in the La Ronge Gold Belt, and are contiguous with Trident’s extensive land holdings in the area.
The agreement is not an arm’s-length transaction, as such term is defined in the TSX Venture Exchange’s Policy 1.1, and therefore constitutes a related party transaction, as such term is defined in Multilateral Instrument 61-101, Protection of Minority Security Holders in Special Transactions. Tim Termuende is a director and officer of Eagle Plains, and is also a director of Trident.
In respect of the requirements of MI 61-101 and exchange Policy 5.9, the Company is relying on the exemptions from the formal valuation and minority approval required under MI 61-101. The Company is exempt from the formal valuation requirement of MI 61-101 in reliance of sections 5.5(b) as no securities of the Company are listed on the specified markets outlined therein. Additionally, the Company is exempt from minority shareholder approval of MI 61-101 in reliance of Section 5.7(1)(a) (fair market value not more than 25 per cent of the Company’s market capitalization).
In accordance with the exchange Policy 5.3, the agreement constitutes a reviewable transaction, as such transaction involves a non-arm’s-length party.
The agreement is subject to acceptance by the TSX Venture Exchange.
Qualified Persons
Charles C. Downie, P.Geo., a “qualified person” for the purposes of National Instrument 43-101 – Standards of Disclosure for Mineral Projects and an officer and director of Eagle Plains, has reviewed and approved the scientific and technical disclosure in this news release.
About Eagle Plains Resources
Based in Cranbrook, B.C., Eagle Plains is a well-funded, prolific project generator that continues to conduct research, acquire and explore mineral projects throughout western Canada, with a focus on critical metals integral to an increasingly electrified, decarbonized economy.
The Company was formed in 1992 and is the fourth-oldest listed issuer on the TSX-V (and the only one of these four that has not seen a roll-back or restructuring of its shares). Eagle Plains has continued to deliver shareholder value over the years and through numerous spin outs has transferred over $110,000,000 in value directly to its shareholders, with Copper Canyon Resources and Taiga Gold Corp. being notable examples. Eagle Plains latest spinout, Eagle Royalties Ltd. (CSE:”ER”) was listed on May 24, 2023, and on October 30, 2025, ER shareholders overwhelmingly approved a three-cornered amalgamation that resulted in a reverse takeover of Eagle Royalties by Summit Royalty Corp. The resulting issuer is named Summit Royalties Ltd. and trades under the symbol SUM on the TSX Venture Exchange with a market capitalization of over $100M.
On October 2, 2024, Eagle Plains announced the formation of a separate division within the Company that will give Eagle Plains’ shareholders direct exposure to strategic opportunities in Canadian green energy transition. As a wholly owned subsidiary of Eagle Plains, Osprey Power Inc. (“OP”) will focus on identifying and advancing innovative and diverse clean energy project portfolios in target markets throughout Canada, with an initial focus on Western Canada.
Eagle Plains’ core business is acquiring grassroots critical- and precious-metal exploration properties. The Company is committed to steadily enhancing shareholder value by advancing our diverse portfolio of projects toward discovery through collaborative partnerships and development of a highly experienced technical team.
Expenditures from 2010-2025 on Eagle Plains-related projects exceed $41M, the majority of which was funded by third-party partners. This exploration work resulted in approximately 50,000m of diamond-drilling and extensive ground-based exploration work facilitating the advancement of numerous projects at various stages of development.
Throughout the exploration process, our mission is to help maintain prosperous communities by exploring for and discovering resource opportunities while building lasting relationships through honest and respectful business practices.
On behalf of the Board of Directors
“C.C. (Chuck) Downie” P.Geo
President and CEO
For further information on EPL, please contact Andrew Wilson at 1 866 HUNT ORE (486 8673)
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
BRUSSELS, BE AND LONDON, UK / ACCESS Newswire / February 26, 2026 / Proxymity, the digital investor communications platform and Euroclear today announced that Euroclear has acquired a minority stake in the company, becoming a strategic shareholder and client. The investment builds on Proxymity’s strong momentum following the successful close of its Series C funding round last year.
Euroclear’s investment signals continued confidence in Proxymity’s capabilities and supports the further development of its global proxy voting and shareholder disclosure technology, alongside its ongoing international expansion. Through this investment, Euroclear joins Proxymity’s established consortium of global custodians, transfer agents and market infrastructure operators.
A global provider of Financial Market Infrastructure (FMI) services, Euroclear enables domestic and cross-border securities transactions and asset safekeeping worldwide. Proxymity’s platform will be integrated within Euroclear’s corporate actions and governance services, advancing its digital capabilities and strengthening the delivery of seamless, end-to-end services to clients globally. Proxymity looks forward to working closely with Euroclear to deliver digital shareholder communications at a greater scale across global markets.
Dean Little, CEO and Co-Founder at Proxymity said: “Euroclear’s investment and commitment as a client marks an important step in our continued growth. Modernising shareholder communications requires closer collaboration between infrastructure providers and technology platforms, and this partnership reflects that progress. Aligning more closely with post-trade operations is critical to delivering more connected and reliable processes across markets.”
Sebastien Danloy, Chief Business Officer at Euroclear, commented: “This investment reflects Euroclear’s ongoing strategy to support technology that brings true value to clients and ultimately makes their lives easier. By integrating Proxymity’s real-time digital capabilities, we can help clients reduce operational complexity, improve transparency and make voting and shareholder communications faster and more reliable across markets. Working closely with Proxymity allows us to deliver more efficient governance services, reduce manual intervention and provide a better overall client experience.”
About Proxymity
Proxymity is a leading digital investor communications platform connecting the world’s ecosystem of issuers, intermediaries, and investors digitally in real time, bringing transparency, efficiency, and accuracy. Trusted by the world’s largest financial institutions, including some of the world’s top 10 Global Custodians managing over $200 trillion in assets under custody, and counting 96 of the FTSE 100 as clients, it serves over 105 markets worldwide.
Proxymity’s digital-first solutions include Vote Connect, a platform that enables issuers to send and receive meeting announcements, proxy voting, and vote confirmations without distortion or interference, providing unparalleled real-time transparency. Proxymity also offers Shareholder Disclosure, a regulatory solution that gives intermediaries confidence that their disclosure obligations are fulfilled with full visibility.
Proxymity’s ground-breaking technology has been recognised with recent awards in 2025, including Global Custodian’s “Innovation in Digital Proxy Voting” and Editor’s Award for “Outstanding Technology Provider”.
Euroclear group is the financial industry’s trusted provider of post trade services. Guided by its purpose, Euroclear innovates to bring safety, efficiency and connections to financial markets for sustainable economic growth. Euroclear provides settlement and custody of domestic and cross-border securities for bonds, equities and derivatives and investment funds. As a proven, resilient capital market infrastructure, Euroclear is committed to delivering risk-mitigation, automation and efficiency at scale for its global client franchise. The Euroclear group comprises Euroclear Bank, the International CSD, as well as Euroclear Belgium, Euroclear Finland, Euroclear France, Euroclear Nederland, Euroclear Sweden and Euroclear UK & International.
(This release updates the release that posted earlier on February 25, 2026 to update the sub headlines.)
NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year
Company expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day window expected to open in Q2
U.S. regulatory decision for ICOTYDETM (icotrokinra) anticipated in 2026 with potential launch this year
PN-881 Phase 1 completion expected by mid-2026
Pre-clinical pipeline expanded with novel wholly-owned candidates PN-477, an oral and s.c. triple GLP-GIP-GCG agonist and PN-458, an oral and s.c. dual GLP-GIP agonist, and PN-8047, an oral hepcidin functional mimetic
Cash, cash equivalents and marketable securities of $646 million as of December 31, 2025, anticipated to provide cash runway through at least end of 2028
NEWARK, CA / ACCESS Newswire / February 25, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) (“Protagonist” or “the Company”) today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided a corporate update.
“In 2025, Protagonist reached new heights with multiple successful Phase 3 outcomes and two NDA filings of our partnered assets, ICOTYDE and rusfertide,” said Dinesh V. Patel, Ph.D., the Company’s President and CEO. “We see the next 12 to 24 months as a period of significant growth and value creation for Protagonist, driven by a combination of the anticipated regulatory and commercial milestones and royalties from ICOTYDE and rusfertide and the continued advancement of our robust R&D pipeline comprised of the oral IL-17 peptide antagonist, our obesity dual and triple agonists, and our oral hepcidin functional mimetic. We are well equipped to fund all our internal wholly owned programs to clinical proof-of-concept with the cash on hand and potential revenue from the partnered assets.”
Fourth Quarter 2025 Recent Developments and Upcoming Milestones
Rusfertide
Under the terms of its License and Collaboration Agreement with Takeda Pharmaceuticals USA, Inc., Protagonist has the right to opt out of the 50:50 profit and loss sharing arrangement in the U.S. during the 90-day period beginning 120 days after filing of a New Drug Application with the FDA for Rusfertide for polycythemia vera. We currently expect to exercise that right in the second quarter of 2026.
ICOTYDETM (Icotrokinra)
A U.S. regulatory decision is anticipated in 2026, followed by commercial launch this year, if FDA approval is granted.
Primary endpoint enrollment completion is expected in 2026 for:
The Phase 3 ICONIC-ASCEND multicenter, randomized, double-blind, placebo-controlled, and ustekinumab active comparator-controlled study to evaluate the efficacy and safety of icotrokinra for the treatment of participants with moderate to severe plaque psoriasis (NCT06934226).
The Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of icotrokinra for the treatment of biologic-naïve participants with active psoriatic arthritis (NCT06878404).
Clinical Programs
The Company expects its Phase 1 study of PN-881 to be complete by mid-2026, informing subsequent clinical development plans.
Discovery Programs
Recently, Protagonist announced two new wholly owned development candidates:
PN-458, a novel dual GLP-GIP agonist for obesity, and
PN-8047, an oral hepcidin functional mimetic complementing rusfertide, an injectable hepcidin mimetic.
Additionally, the Company added IL-4Rα and amylin as high-priority discovery programs to further expand and strengthen its pipeline.
Fourth Quarter and Full Year 2025 Financial Results
Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents, and marketable securities as of December 31, 2025, were $646.0 million as compared to $559.2 million in the previous year.
Revenue: License and collaboration revenue is derived from the Company’s License and Collaboration Agreement with JNJ, (the “JNJ Agreement”), and its License and Collaboration Agreement with Takeda (the “Takeda Agreement”).
License and collaboration revenue decreased by $163.2 million from $170.6 million for the fourth quarter of 2024 to $7.4 million for the fourth quarter of 2025. License and collaboration revenue decreased by $388.4 million from $434.4 million for the full year 2024 to $46.0 million for the full year 2025. The decrease in revenue was primarily attributable to lower milestone and collaboration revenue, which is highly variable and dependent upon factors such as the timing of when regulatory and sales milestones are achieved, if at all, and the accounting for any upfront payments associated with any existing or new agreements.
License and collaboration revenue of $7.4 million for the fourth quarter of 2025 was comprised of development services we provided during the period under the Takeda Agreement. License and collaboration revenue of $170.6 million for the fourth quarter of 2024 included (i) achievement of a non-refundable $165.0 milestone under the JNJ Agreement, and (ii) development services we provided during the period under the Takeda Agreement.
License and collaboration revenue of $46.0 million for the full year 2025 was comprised of (i) proportional recognition of a $25.0 million milestone earned from Takeda in Q1 25, and (ii) development services we provided during the period under the Takeda agreement. License and collaboration revenue of $434.4 million for the full year 2024 included (i) $254.1 million of the $300.0 million initial transaction price for the Takeda Agreement allocated to the rusfertide license upon effectiveness of the agreement, (ii) achievement of a non-refundable $165.0 milestone under the JNJ Agreement earned in Q4 24, and (iii) development services we provided during the period under the Takeda Agreement.
Research and Development Expenses: Increased by $11.5 million and $21.2 million for the fourth quarter and full year 2025, respectively, from the prior year periods. The increases were due primarily to increases in drug discovery and pre-clinical research expenses, including expenses related to our IL-17 product candidate PN-881 and our obesity product candidates.
General and Administrative Expenses: Increased by $2.5 million for the three months ended December 31, 2025, from the prior year period primarily due to increases in professional services and personnel-related expenses. The increase of $1.4 million for the full year 2025 as compared to the prior year was primarily due to increases in professional services and personnel-related expenses, partially offset by $4.6 million in one-time advisory and legal fees in 2024 related to the Takeda Agreement.
Net (Loss) Income: Net loss was $44.4 million, or $0.69 per basic share and diluted share, for the fourth quarter of 2025 as compared to net income of $131.7 million, or $2.11 per basic share and $1.98 per diluted share, for the fourth quarter of 2024. Net loss was $130.1 million, or $2.05 per basic share and diluted share, for the full year 2025, as compared to net income of $275.2 million, or $4.47 per basic share and $4.23 per diluted share, for the full year 2024.
About Protagonist Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced Phase 3 clinical development, with a New Drug Application (NDA) for ICOTYDETM (icotrokinra) under review at the FDA and an NDA for rusfertide submitted in December 2025. ICOTYDE is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”), which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following ICOTYDE’s joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies’ IL-23R collaboration, Protagonist was primarily responsible for the development of ICOTYDE through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in development for the rare blood disorder polycythemia vera. Rusfertide is being co-developed and may be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement under which the Company was primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including an oral IL-17 peptide antagonist, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company’s website at https://www.protagonist-inc.com/.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding potential timing of regulatory actions, clinical trial results, and potential revenue from the Company’s collaborations with Takeda and Johnson & Johnson. In some cases, you can identify these statements by forward-looking words such as “anticipate,” “believe,” “may,” “will,” “expect,” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading “Risk Factors” contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition, and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this press release.
NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year
Company expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day window expected to open in Q2
U.S. regulatory decision for ICOTYDETM (icotrokinra) anticipated in 2026 with potential launch this year
PN-881 Phase 1 completion expected by mid-2026
NEWARK, CALIFORNIA / ACCESS Newswire / February 25, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) (“Protagonist” or “the Company”) today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided a corporate update.
“In 2025, Protagonist reached new heights with multiple successful Phase 3 outcomes and two NDA filings of our partnered assets, ICOTYDE and rusfertide,” said Dinesh V. Patel, Ph.D., the Company’s President and CEO. “We see the next 12 to 24 months as a period of significant growth and value creation for Protagonist, driven by a combination of the anticipated regulatory and commercial milestones and royalties from ICOTYDE and rusfertide and the continued advancement of our robust R&D pipeline comprised of the oral IL-17 peptide antagonist, our obesity dual and triple agonists, and our oral hepcidin functional mimetic. We are well equipped to fund all our internal wholly owned programs to clinical proof-of-concept with the cash on hand and potential revenue from the partnered assets.”
Fourth Quarter 2025 Recent Developments and Upcoming Milestones
Rusfertide
Under the terms of its License and Collaboration Agreement with Takeda Pharmaceuticals USA, Inc., Protagonist has the right to opt out of the 50:50 profit and loss sharing arrangement in the U.S. during the 90-day period beginning 120 days after filing of a New Drug Application with the FDA for Rusfertide for polycythemia vera. We currently expect to exercise that right in the second quarter of 2026.
ICOTYDETM (Icotrokinra)
A U.S. regulatory decision is anticipated in 2026, followed by commercial launch this year, if FDA approval is granted.
Primary endpoint enrollment completion is expected in 2026 for:
The Phase 3 ICONIC-ASCEND multicenter, randomized, double-blind, placebo-controlled, and ustekinumab active comparator-controlled study to evaluate the efficacy and safety of icotrokinra for the treatment of participants with moderate to severe plaque psoriasis (NCT06934226).
The Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of icotrokinra for the treatment of biologic-naïve participants with active psoriatic arthritis (NCT06878404).
Clinical Programs
The Company expects its Phase 1 study of PN-881 to be complete by mid-2026, informing subsequent clinical development plans.
Discovery Programs
Recently, Protagonist announced two new wholly owned development candidates:
PN-458, a novel dual GLP-GIP agonist for obesity, and
PN-8047, an oral hepcidin functional mimetic complementing rusfertide, an injectable hepcidin mimetic.
Additionally, the Company added IL-4Rα and amylin as high-priority discovery programs to further expand and strengthen its pipeline.
Fourth Quarter and Full Year 2025 Financial Results
Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents, and marketable securities as of December 31, 2025, were $646.0 million as compared to $559.2 million in the previous year.
Revenue: License and collaboration revenue is derived from the Company’s License and Collaboration Agreement with JNJ, (the “JNJ Agreement”), and its License and Collaboration Agreement with Takeda (the “Takeda Agreement”).
License and collaboration revenue decreased by $163.2 million from $170.6 million for the fourth quarter of 2024 to $7.4 million for the fourth quarter of 2025. License and collaboration revenue decreased by $388.4 million from $434.4 million for the full year 2024 to $46.0 million for the full year 2025. The decrease in revenue was primarily attributable to lower milestone and collaboration revenue, which is highly variable and dependent upon factors such as the timing of when regulatory and sales milestones are achieved, if at all, and the accounting for any upfront payments associated with any existing or new agreements.
License and collaboration revenue of $7.4 million for the fourth quarter of 2025 was comprised of development services we provided during the period under the Takeda Agreement. License and collaboration revenue of $170.6 million for the fourth quarter of 2024 included (i) achievement of a non-refundable $165.0 milestone under the JNJ Agreement, and (ii) development services we provided during the period under the Takeda Agreement.
License and collaboration revenue of $46.0 million for the full year 2025 was comprised of (i) proportional recognition of a $25.0 million milestone earned from Takeda in Q1 25, and (ii) development services we provided during the period under the Takeda agreement. License and collaboration revenue of $434.4 million for the full year 2024 included (i) $254.1 million of the $300.0 million initial transaction price for the Takeda Agreement allocated to the rusfertide license upon effectiveness of the agreement, (ii) achievement of a non-refundable $165.0 milestone under the JNJ Agreement earned in Q4 24, and (iii) development services we provided during the period under the Takeda Agreement.
Research and Development Expenses: Increased by $11.5 million and $21.2 million for the fourth quarter and full year 2025, respectively, from the prior year periods. The increases were due primarily to increases in drug discovery and pre-clinical research expenses, including expenses related to our IL-17 product candidate PN-881 and our obesity product candidates.
General and Administrative Expenses: Increased by $2.5 million for the three months ended December 31, 2025, from the prior year period primarily due to increases in professional services and personnel-related expenses. The increase of $1.4 million for the full year 2025 as compared to the prior year was primarily due to increases in professional services and personnel-related expenses, partially offset by $4.6 million in one-time advisory and legal fees in 2024 related to the Takeda Agreement.
Net (Loss) Income: Net loss was $44.4 million, or $0.69 per basic share and diluted share, for the fourth quarter of 2025 as compared to net income of $131.7 million, or $2.11 per basic share and $1.98 per diluted share, for the fourth quarter of 2024. Net loss was $130.1 million, or $2.05 per basic share and diluted share, for the full year 2025, as compared to net income of $275.2 million, or $4.47 per basic share and $4.23 per diluted share, for the full year 2024.
About Protagonist Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced Phase 3 clinical development, with a New Drug Application (NDA) for ICOTYDETM (icotrokinra) under review at the FDA and an NDA for rusfertide submitted in December 2025. ICOTYDE is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”), which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following ICOTYDE’s joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies’ IL-23R collaboration, Protagonist was primarily responsible for the development of ICOTYDE through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in development for the rare blood disorder polycythemia vera. Rusfertide is being co-developed and may be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement under which the Company was primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including an oral IL-17 peptide antagonist, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company’s website at https://www.protagonist-inc.com/.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding potential timing of regulatory actions, clinical trial results, and potential revenue from the Company’s collaborations with Takeda and Johnson & Johnson. In some cases, you can identify these statements by forward-looking words such as “anticipate,” “believe,” “may,” “will,” “expect,” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading “Risk Factors” contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition, and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this press release.
The show broadcasts as sponsored programming with national TV commercials from Synergy CHC (NASDAQ:SNYR), NeOnc Technologies (NASDAQ:NTHI), PetVivo (OTCQX:PETV), and YY Group Holdings (NASDAQ:YYGH).
NEW YORK CITY, NEW YORK / ACCESS Newswire / February 14, 2026 / New to The Street , the nationally syndicated, long-form television and digital business platform, today announced the upcoming broadcast of Show #726 , airing on Bloomberg Television at 6:30 PM EST across the United States , 12:30 PM local time across MENA , and distributed throughout Latin America as sponsored programming.
This week’s broadcast features executive interviews and strategic updates from:
Vivos Therapeutics (NASDAQ:VVOS) – A medical technology company pioneering non-invasive treatments for obstructive sleep apnea and dentofacial abnormalities.
Aeries Technology (NASDAQ:AERT) – A global professional services and technology consulting firm focused on digital transformation and enterprise growth solutions.
Virtuix Holdings (NASDAQ:VTIX) – The innovator behind the Omni® platform, redefining immersive virtual reality experiences for consumer and enterprise applications.
Stardust Power (NASDAQ:SDST) – A U.S.-based developer of battery-grade lithium refining capacity supporting the domestic electric vehicle and energy storage supply chain.
The broadcast delivers in-depth executive interviews, growth strategy discussions, and forward-looking corporate positioning tailored to institutional investors, analysts, and retail shareholders across multiple global markets.
In addition to featured interviews, the program includes nationally distributed television commercials from:
Synergy CHC Corp. (NASDAQ:SNYR)
NeOnc Technologies Holdings (NASDAQ:NTHI)
PetVivo Holdings Inc. (OTCQB:PETV)
YY Group Holding Limited (NASDAQ:YYGH)
These commercial placements air predominately during financial programming hours, reinforcing brand positioning and investor visibility across Bloomberg’s U.S., MENA, and Latin American distribution footprint.
“Show 726 reflects the continued demand for credible, long-form storytelling combined with global television reach,” said Vince Caruso, Co Founder and CEO of New to The Street. “Broadcasting across the U.S., MENA, and Latin America – supported by one of the most powerful digital financial media ecosystems in the world – allows our clients to communicate directly with a global investor audience.”
About New to The Street
New to The Street is one of the longest-running business television brands in the United States, broadcasting weekly as sponsored programming on Bloomberg Television and Fox Business for over 17 years.
The platform integrates:
Nationwide U.S. linear television distribution
International reach across MENA and Latin America
One of the fastest-growing financial YouTube channels globally with over 4.5 million subscribers
Guaranteed social media amplification across YouTube, LinkedIn, X, Instagram, and Facebook
Strategic outdoor billboard placements in Times Square and the NYC Financial District
Unlike traditional “best efforts” media models, New to The Street combines long-form television, digital broadcast, social amplification, and iconic outdoor exposure into a unified, predictable media platform designed to elevate corporate visibility, strengthen investor awareness, and support capital markets positioning.
With a 17-year track record of consistent national and international broadcasts, New to The Street continues to expand its global footprint while delivering institutional-grade production quality and multi-channel distribution at scale.
Sustained acoustic medicine (sam®) helps players recover more quickly from workouts and injuries, such as the UCL tears, hamstring pulls, and oblique strains that are becoming more common in baseball.
TRUMBULL, CONNECTICUT / ACCESS Newswire / February 12, 2026 / As pitchers and catchers report next week to baseball’s spring training camps, ZetrOZ Systems will also be there, meeting with teams to present its sustained acoustic medicine (sam®) technology. The company’s sam® wearable ultrasound device is proven effective in helping athletes recover from workouts, avoid health issues and recover more quickly from common soft-tissue injuries.
ZetrOZ Systems has previously worked with the Professional Baseball Athletic Trainers Society to educate teams about how the device can assist in treating the most common baseball injuries: rotator cuff tears, UCL injuries, labral tears, hamstring and ankle sprains and tendonitis.
Those injuries are a growing problem in Major League Baseball. A 2024 MLB study found that major and minor league UCL surgeries have “increased substantially” since 2021. The report highlighted 41 UCL surgeries for major league players and 240 surgeries for minor league players in 2024.
Baseball injuries also occur more frequently during training camp and early in the season. The Orthopaedic Journal of Sports Medicine’s 2019 study found that about 40% of hamstring injuries in baseball occur in April and May. The Journal of Shoulder and Elbow Surgery’s 2021 report established that UCL injuries in baseball also peaked in the spring.
“Spring training is the time when baseball players prepare for the long road of the regular season, and it’s also when they may be most vulnerable to injury,” said Dr. George K. Lewis, founder and CEO of ZetrOZ Systems and the inventor of sustained acoustic medicine. “Our sam® wearable ultrasound technology provides athletes with a clinically proven way to accelerate recovery and optimize performance. We’re hopeful that by meeting with teams this spring, we can help them keep their players healthy all the way to the World Series.”
The sam® long-duration ultrasound device works by generating warmth deep into soft tissue, increasing blood flow and delivery of oxygenated hemoglobin at the site. That removes cytokine enzymes and cellular waste, which reduces pain and inflammation, improves function and range of motion, and shortens recovery time after workouts or injuries.
The effectiveness of sustained acoustic medicine and the sam® device has been documented in more than 20 Level 1-5 clinical studies and more than 40 peer-reviewed journal articles. The sam® device is also the only wearable ultrasound unit with FDA clearance for daily home use, which allows it to fit seamlessly into an athlete’s routine. Players can use the portable device while traveling or relaxing, making therapy and rehabilitation more manageable.
The sam® device from ZetrOZ Systems helps both professional athletes and everyday people return to sports and daily activities without invasive treatments or potentially addictive pain medication. For more information about ZetrOZ Systems and the sam® wearable ultrasound device, visit www.zetroz.com or www.samrecover.com.
About ZetrOZ Systems
ZetrOZ Systems is leading the way in healing innovations in sports medicine, developing wearable bioelectronic devices to deliver sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of 46 patents and is the exclusive manufacturer and developer of the sam® product line, designed to treat acute and chronic musculoskeletal conditions.
